Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
rosacea  	rosacea  	 VBG	O
A  	A  	 DT	O
range  	range  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	B-NP
options  	options  	 NNS	I-NP
are  	are  	 VBP	O
available  	available  	 JJ	O
in  	in  	 IN	O
rosacea 	rosacea 	 NN	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
include  	include  	 VBP	O
several  	several  	 JJ	O
topical  	topical  	 NNS	O
( 	( 	 -LRB-	O
mainly  	mainly  	 RB	O
metronidazole 	metronidazole 	 JJ	O
,  	,  	 ,	O
azelaic  	azelaic  	 JJ	B-NP
acid 	acid 	 NN	I-NP
,  	,  	 ,	O
other  	other  	 JJ	O
antibiotics 	antibiotics 	 NN	O
,  	,  	 ,	O
sulfur 	sulfur 	 NN	B-NP
,  	,  	 ,	O
retinoids 	retinoids 	 CD	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
oral  	oral  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
( 	( 	 -LRB-	O
mainly  	mainly  	 RB	O
tetracyclines 	tetracyclines 	 JJ	O
,  	,  	 ,	O
metronidazole 	metronidazole 	 NN	B-NP
,  	,  	 ,	O
macrolides 	macrolides 	 CD	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
some  	some  	 DT	O
cases 	cases 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
first  	first  	 JJ	O
choice  	choice  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
systemic  	systemic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
because  	because  	 IN	O
patients  	patients  	 NNS	O
may  	may  	 MD	O
have  	have  	 VB	O
sensitive  	sensitive  	 JJ	B-NP
skin  	skin  	 NN	I-NP
and  	and  	 CC	O
topical  	topical  	 JJ	B-NP
medications  	medications  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
irritant 	irritant 	 NNS	O
.  	.  	 .	O
Isotretinoin  	Isotretinoin  	 NNP	B-NP
can  	can  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
in  	in  	 IN	O
resistant  	resistant  	 JJ	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
rosacea 	rosacea 	 NN	B-NP
.  	.  	 .	O
Unfortunately 	Unfortunately 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
majority  	majority  	 NN	O
of  	of  	 IN	O
studies  	studies  	 NNS	O
on  	on  	 IN	O
rosacea  	rosacea  	 JJ	B-NP
treatments  	treatments  	 NNS	I-NP
are  	are  	 VBP	O
at  	at  	 IN	O
high  	high  	 JJ	O
or  	or  	 CC	O
unclear  	unclear  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
bias 	bias 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
recent  	recent  	 JJ	O
Cochrane  	Cochrane  	 JJ	B-NP
review  	review  	 NN	I-NP
found  	found  	 VBD	O
that  	that  	 IN	O
only  	only  	 RB	O
topical  	topical  	 JJ	B-NP
metronidazole 	metronidazole 	 NN	I-NP
,  	,  	 ,	O
azelaic  	azelaic  	 JJ	B-NP
acid 	acid 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
oral  	oral  	 JJ	B-NP
doxycycline  	doxycycline  	 NNS	I-NP
( 	( 	 -LRB-	O
40  	40  	 CD	O
mg 	mg 	 CD	B-NP
)  	)  	 -RRB-	O
had  	had  	 VBD	O
some  	some  	 DT	O
evidence  	evidence  	 NN	O
to  	to  	 TO	O
support  	support  	 VB	O
their  	their  	 PRP$	O
effectiveness  	effectiveness  	 NN	O
in  	in  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
rosacea  	rosacea  	 NN	B-NP
and  	and  	 CC	O
concluded  	concluded  	 VBD	O
that  	that  	 DT	O
further  	further  	 JJ	O
well-designed 	well-designed 	 NN	O
,  	,  	 ,	O
adequately-powered  	adequately-powered  	 JJ	O
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
are  	are  	 VBP	O
required 	required 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
our  	our  	 PRP$	O
practice 	practice 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
evaluate  	evaluate  	 VB	O
our  	our  	 PRP$	O
patients  	patients  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
two  	two  	 CD	O
possible  	possible  	 JJ	O
triggers 	triggers 	 NN	O
,  	,  	 ,	O
Helicobacter  	Helicobacter  	 NNP	B-NP
pylori  	pylori  	 JJ	I-NP
infection  	infection  	 NN	I-NP
and  	and  	 CC	O
small  	small  	 JJ	O
intestinal  	intestinal  	 JJ	B-NP
bacterial  	bacterial  	 JJ	I-NP
overgrowth 	overgrowth 	 NN	I-NP
.  	.  	 .	O
When  	When  	 WRB	O
they  	they  	 PRP	O
are  	are  	 VBP	O
present  	present  	 RB	O
we  	we  	 PRP	O
use  	use  	 VBP	O
adapted  	adapted  	 VBN	O
antibiotic  	antibiotic  	 JJ	B-NP
protocols 	protocols 	 NNS	I-NP
.  	.  	 .	O
If  	If  	 IN	O
not 	not 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
use  	use  	 VBP	O
oral  	oral  	 JJ	B-NP
metronidazole  	metronidazole  	 NN	I-NP
or  	or  	 CC	O
oral  	oral  	 JJ	B-NP
tetracycline  	tetracycline  	 NN	I-NP
to  	to  	 TO	O
treat  	treat  	 VB	O
papulopustolar  	papulopustolar  	 JJ	B-NP
rosacea 	rosacea 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
also  	also  	 RB	O
look  	look  	 VB	O
for  	for  	 IN	O
Demodex  	Demodex  	 NNP	B-NP
folliculorum  	folliculorum  	 JJ	I-NP
infestation 	infestation 	 NN	I-NP
.  	.  	 .	O
When  	When  	 WRB	O
Demodex  	Demodex  	 NNP	B-NP
concentration  	concentration  	 NN	I-NP
is  	is  	 VBZ	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
5 	5 	 CD	O
/ 	/ 	 CD	O
cm 	cm 	 NNS	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
)  	)  	 -RRB-	I-NP
we  	we  	 PRP	O
use  	use  	 VBP	O
topical  	topical  	 JJ	B-NP
crotamiton  	crotamiton  	 NN	I-NP
10 	10 	 CD	O
%  	%  	 NN	O
or  	or  	 CC	O
metronidazole 	metronidazole 	 NN	B-NP
.  	.  	 .	O
